Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

Abstract

The emergence of the SARS-CoV-2 variant of concern Omicron (Pango lineage B.1.1.529), first identified in Botswana and South Africa, may compromise vaccine effectiveness and lead to re-infections 1 . Here we investigated Omicron escape from neutralization by antibodies from South African individuals vaccinated with Pfizer BNT162b2. We used blood samples taken soon after vaccination from individuals who were vaccinated and previously infected with SARS-CoV-2 or vaccinated with no evidence of previous infection. We isolated and sequence-confirmed live Omicron virus from an infected person and observed that Omicron requires the angiotensin-converting enzyme 2 (ACE2) receptor to infect cells. We compared plasma neutralization of Omicron relative to an ancestral SARS-CoV-2 strain and found that neutralization of ancestral virus was much higher in infected and vaccinated individuals compared with the vaccinated-only participants. However, both groups showed a 22-fold reduction in vaccine-elicited neutralization by the Omicron variant. Participants who were vaccinated and had previously been infected exhibited residual neutralization of Omicron similar to the level of neutralization of the ancestral virus observed in the vaccination-only group. These data support the notion that reasonable protection against Omicron may be maintained using vaccination approaches.

Full text

Its licence does not allow us to show the full text. Read it at PubMed Central:

References 21

1. 1.
   Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa · 2022

   No notice
2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41586-021-03471-w

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1016/j.chom.2021.10.003

4. 4.
   mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection · 2021

   No notice
5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41591-021-01325-6

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41586-021-03402-9

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1016/j.cell.2021.03.013

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library10.1038/s41591-021-01285-x

9. 9.
   Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera · 2021

   No notice
10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41591-021-01318-5

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-021-03398-2

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41586-021-03324-6

13. 13.
    Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis · 2022

    No notice
14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1038/s41591-021-01377-8

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.
    Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants · 2020

    No notice
17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1056/nejmoa2114228

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1056/nejmoa2114114

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.chom.2021.10.003

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library10.1016/j.xcrm.2021.100355

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

Cited by papers we hold 47

• Quantitative characterisation of extracellular vesicles designed to decoy or compete with SARS-CoV-2 reveals differential mode of action across variants of concern and highlights the diversity of Omicron · 2025
  Not checked
• Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination · 2023
  Not checked
• Evaluation of Waning of SARS-CoV-2 Vaccine–Induced Immunity · 2023
  No notice
• Predicting vaccine effectiveness against severe COVID-19 over time and against variants: a meta-analysis · 2023
  No notice
• Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies · 2023
  No notice
• Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection · 2023
  No notice
• A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies · 2023
  No notice
• Antibody evasion properties of SARS-CoV-2 Omicron sublineages · 2022
  No notice
• SARS‐CoV‐2 Omicron variant: A next phase of the COVID‐19 pandemic and a call to arms for system sciences and precision medicine · 2022
  Not checked
• Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes · 2022
  No notice
• A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies · 2022
  No notice
• Rapid Evaluation of Vaccine Booster Effectiveness against SARS-CoV-2 Variants · 2022
  Not checked
• Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission · 2022
  No notice
• Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity · 2022
  Not checked
• COVID-19 pandemic dynamics in South Africa and epidemiological characteristics of three variants of concern (Beta, Delta, and Omicron) · 2022
  Not checked
• Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models · 2022
  No notice
• Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study · 2022
  No notice
• Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies · 2022
  Not checked
• Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529 · 2022
  No notice
• Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera · 2022
  No notice

and 27 more

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.